Oramed Pharmaceuticals (ORMP) Stock: Buy, Sell, or Hold?
ORMP - Oramed Pharmaceuticals Inc.
$4.49
0.01 (0.22%)
▲
5d:
-5.07%
30d:
-11.44%
90d:
-1.75%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 12, 2026
Get Alerted When ORMP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ORMP shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ORMP shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: ORMP is currently trading at $4.49, which is considered oversold relative to its 30-day fair value range of $4.61 to $5.00.
Technical Outlook: Technically, ORMP is showing support break momentum. The price is currently testing key support at $4.39. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ORMP scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.00 (+55.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ORMP is showing support break momentum. The price is currently testing key support at $4.39. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ORMP scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.00 (+55.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.61 -
$5.00
Company Quality Score
32/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (36/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 55.9% below Wall St target ($7.00)
- WARNING: Composite score 32/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.61 -
$5.00
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$4.39
Resistance Level
$4.90
Current Trend
Support Break
Technical data as of
Oct 2, 2026
Fundamental Context
Wall Street Target
$7.00
(+55.9%)
Revenue Growth (YoY)
-100.0%
Earnings Growth (YoY)
493.5%
Share & Embed Analysis
Last updated: October 04, 2026 4:36 AM ET
Data refreshes hourly during market hours. Next update: 5:36 AM
Data refreshes hourly during market hours. Next update: 5:36 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ORMP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$371 | 49 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 56 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$570 | 55 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$310 | 66 BUY |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$63 | 60 BUY |
